Physician profile
Kenneth A Wallace
NPI 1295791754
$26,454.88
in general payments reported to CMS, 2019-2025
24 companies · $22K in 2025
The $22K reported for 2025 was more than what 98% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.41 · 2020: $20.78 · 2021: $172 · 2022: $131 · 2023: $1,113 · 2024: $2,835 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $24K · Food and Beverage: $2,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $23,889.20 |
| Food and Beverage | $2,165.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $23,985.23 | 2023-2025 | Ameluz, Bf-Rhodoled, Ameluz |
| Janssen Biotech, INC. | $450.19 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $433.08 | 2023-2025 | Dupixent |
| Abbvie INC. | $272.28 | 2022-2025 | Skyrizi, Humira |
| Smith+Nephew, INC. | $178.99 | 2021-2023 | Grafix Pl, Collagenase Santyl |
| Strata Skin Sciences, INC. | $168.11 | 2025 | Xtrac |
| Organogenesis INC. | $144.82 | 2020-2023 | Puraply |
| Genzyme Corporation | $131.79 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $131.10 | 2022-2024 | Ilumya, Blu-U, Odomzo |
| Convatec INC. | $113.76 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $75.92 | 2023-2024 | |
| Kerecis Limited | $60.18 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
| Pfizer INC. | $54.50 | 2022-2023 | |
| Novo Nordisk INC | $41.62 | 2022-2023 | Wegovy |
| Leo Pharma INC. | $34.98 | 2023-2024 | Adbry |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sensus Healthcare, INC. | $32.48 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $24.63 | 2019 | |
| Amgen INC. | $23.75 | 2023 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.02 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.73 | 2021 | |
| Incyte Corporation | $16.23 | 2023 | Opzelura |
| Genentech USA, INC. | $15.24 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.50 | 2019 | |
| Allergan, INC. | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.